Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Medical management of Peyronie's disease.

Hellstrom WJ.

J Androl. 2009 Jul-Aug;30(4):397-405. doi: 10.2164/jandrol.108.006221. Epub 2008 Oct 30. Review.

2.

Pharmacological Management of Peyronie's Disease.

Trost LW, Gur S, Hellstrom WJ.

Drugs. 2007;67(4):527-45. Review.

PMID:
17352513
3.

[Pathophysiology and management of Peyronie's disease in adult patients: an update].

Alenda O, Beley S, Ferhi K, Cour F, Chartier-Kastler E, Haertig A, Richard F, Rouprêt M.

Prog Urol. 2010 Feb;20(2):91-100. doi: 10.1016/j.purol.2009.05.010. Epub 2009 Jul 3. Review. French.

PMID:
20142049
4.

Current status and new developments in Peyronie's disease: medical, minimally invasive and surgical treatment options.

Gur S, Limin M, Hellstrom WJ.

Expert Opin Pharmacother. 2011 Apr;12(6):931-44. doi: 10.1517/14656566.2011.544252. Review.

PMID:
21405946
5.
6.
7.

The impact of intralesional interferon alpha-2b injection therapy on penile hemodynamics in men with Peyronie's disease.

Kendirci M, Usta MF, Matern RV, Nowfar S, Sikka SC, Hellstrom WJ.

J Sex Med. 2005 Sep;2(5):709-15.

PMID:
16422829
8.

A critical analysis of nonsurgical treatment of Peyronie's disease.

Hauck EW, Diemer T, Schmelz HU, Weidner W.

Eur Urol. 2006 Jun;49(6):987-97. Epub 2006 Mar 20. Review.

PMID:
16698449
9.

Safety and tolerability of local treatment with iloprost, a prostacyclin analogue, in patients with Peyronie's disease: a phase I study.

Pavone C, Napoli G, Caruana G, Alonge V, Usala M, Abbadessa D.

BJU Int. 2012 Jul;110(1):117-21. doi: 10.1111/j.1464-410X.2011.10733.x. Epub 2011 Dec 16.

10.

Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease.

Hellstrom WJ, Kendirci M, Matern R, Cockerham Y, Myers L, Sikka SC, Venable D, Honig S, McCullough A, Hakim LS, Nehra A, Templeton LE, Pryor JL.

J Urol. 2006 Jul;176(1):394-8.

PMID:
16753449
11.

Intralesional interferon-alpha-2b for the treatment of Peyronie's disease.

Lacy GL 2nd, Adams DM, Hellstrom WJ.

Int J Impot Res. 2002 Oct;14(5):336-9. Review.

12.

Minimally invasive treatment of Peyronie's disease: evidence-based progress.

Jordan GH, Carson CC, Lipshultz LI.

BJU Int. 2014 Jul;114(1):16-24. doi: 10.1111/bju.12634. Review.

13.

Combined intralesional interferon alpha 2B and oral vitamin E in the treatment of Peyronie's disease.

Novak TE, Bryan W, Templeton L, Sikka S, Hellstrom WJ.

J La State Med Soc. 2001 Jul;153(7):358-63.

PMID:
11519219
14.
15.

Peyronie's disease: review of nonsurgical treatment options.

Larsen SM, Levine LA.

Urol Clin North Am. 2011 May;38(2):195-205. doi: 10.1016/j.ucl.2011.02.006. Review.

PMID:
21621086
16.

[Conservative therapy of Peyronie's disease - update 2015].

Hatzichristodoulou G.

Urologe A. 2015 May;54(5):641-7. doi: 10.1007/s00120-015-3796-1. Review. German.

PMID:
25987328
17.

Management of Peyronie's disease--a review.

Tunuguntla HS.

World J Urol. 2001 Aug;19(4):244-50. Review.

PMID:
11550782
18.

Peironimev-Plus® in the treatment of chronic inflammation of tunica albuginea (Peyronie's disease). results of a controlled study.

Paulis G, Cavallini G, Brancato T, Alvaro R.

Inflamm Allergy Drug Targets. 2013 Feb;12(1):61-7.

PMID:
23004005
19.

Intralesional interferon-alpha-2B injections for the treatment of Peyronie's disease.

Dang G, Matern R, Bivalacqua TJ, Sikka S, Hellstrom WJ.

South Med J. 2004 Jan;97(1):42-6.

PMID:
14746421
20.

Therapeutic advances in the treatment of Peyronie's disease.

Yafi FA, Pinsky MR, Sangkum P, Hellstrom WJ.

Andrology. 2015 Jul;3(4):650-60. doi: 10.1111/andr.12058. Epub 2015 Jun 20. Review.

Supplemental Content

Support Center